Therefore, the relationship between RAD18, DNA damage tolerance, the hypermutator phenotype, and clinical outcome must be clarified using in vivo models in order to validate the RAD18 signaling axis as a therapeutic target in glioblastoma. This evidence concerns the gene RAD18 and glioblastoma.